Toronto Dominion Bank Has $14.08 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Toronto Dominion Bank decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.5% during the 1st quarter, HoldingsChannel.com reports. The firm owned 55,659 shares of the medical research company’s stock after selling 3,249 shares during the period. Toronto Dominion Bank’s holdings in IQVIA were worth $14,076,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Mutual Advisors LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $217,000. HB Wealth Management LLC grew its position in IQVIA by 38.7% in the fourth quarter. HB Wealth Management LLC now owns 2,202 shares of the medical research company’s stock valued at $509,000 after purchasing an additional 614 shares in the last quarter. CVA Family Office LLC bought a new stake in IQVIA during the 4th quarter worth about $43,000. Great Lakes Retirement Inc. boosted its stake in shares of IQVIA by 5.2% during the 4th quarter. Great Lakes Retirement Inc. now owns 2,309 shares of the medical research company’s stock worth $534,000 after buying an additional 115 shares during the last quarter. Finally, Good Life Advisors LLC bought a new position in shares of IQVIA in the 4th quarter valued at about $210,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IQV. The Goldman Sachs Group initiated coverage on IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. Truist Financial raised their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday. UBS Group upped their price target on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird lifted their price objective on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Monday, July 15th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $263.56.

IQVIA Stock Performance

Shares of IQV traded up $7.38 during mid-day trading on Friday, hitting $239.67. 1,185,316 shares of the company’s stock were exchanged, compared to its average volume of 1,091,180. The company has a quick ratio of 0.88, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm has a market cap of $43.69 billion, a price-to-earnings ratio of 32.74, a price-to-earnings-growth ratio of 2.24 and a beta of 1.49. The stock’s 50-day simple moving average is $220.23 and its 200-day simple moving average is $229.41. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the prior year, the company posted $2.22 EPS. The company’s revenue was up 2.3% compared to the same quarter last year. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.13 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.